TABLE 1.
Usage of MA104 cell α2β1, β2, and αVβ3 integrins for infection by rotaviruses and their reassortants
| Rotavirusa | Serotypeb
|
SA usagec | % Infectivity blockade by given MAb (mean ± SD)d
|
|||
|---|---|---|---|---|---|---|
| P (VP4) | G (VP7) | Anti-α2 | Anti-β2 | Anti-αVβ3 | ||
| Bo/NCDV | 6[1] | 6 | + | 33 ± 3 | 26 ± 5 | 18 ± 5 |
| Si/SA11 | 5B[2] | 3 | + | 42 ± 6 | 40 ± 5 | 21 ± 1 |
| UK×SA11 | 5B[2] | 6 | (+) | 32 ± 3 | 1 ± 1 | 1 ± 1 |
| TFR-41×SA11 | 5B[2] | 5 | (+) | 30 ± 4 | 0 ± 1 | 0 ± 1 |
| K8×SA11 | 5B[2] | 1 | (+) | 32 ± 8 | 28 ± 8 | 34 ± 9 |
| RV-5×SA11 | 5B[2] | 2 | (+) | 22 ± 6 | 20 ± 4 | ND |
| Si/RRV | 5B[3] | 3 | + | 35 ± 3 | 31 ± 6 | 25 ± 6 |
| UK×RRV | 5B[3] | 6 | (+) | 28 ± 1 | 1 ± 1 | 1 ± 1 |
| Ty-1×RRV | 5B[3] | 7 | (+) | 23 ± 2 | 2 ± 1 | 0 ± 1 |
| Hu/RV-5 | 1B[4] | 2 | (−) | 30 ± 1 | 32 ± 1 | 28 ± 0 |
| Bo/UK | 7[5] | 6 | − | −2 ± 2 | 0 ± 2 | 0 ± 1 |
| RRV×UK | 7[5] | 3 | (−) | 0 ± 1 | 22 ± 2 | 33 ± 7 |
| MDR-13×UK | 7[5] | 3 and 5 | (−) | −3 ± 7 | −2 ± 6 | 4 ± 5 |
| Hu/M37 | 2A[6] | 1 | − | −4 ± 2 | −2 ± 2 | 2 ± 1 |
| Hu/1076 | 2A[6] | 2 | − | 0 ± 2 | −4 ± 3 | 2 ± 3 |
| Hu/RV-3, S12/85 | 2A[6] | 3 | (−) | 1 ± 5 | −1 ± 2 | 4 ± 7 |
| Hu/ST-3 | 2A[6] | 4 | − | −3 ± 1 | −4 ± 5 | 1 ± 3 |
| Po/BEN-144 | 2B[6] | 4 | (−) | 2 ± 4 | 0 ± 4 | 0 ± 4 |
| Po/CRW-8, AT76 | 9[7] | 3 | + | 1 ± 1 | 1 ± 1 | 0 ± 2 |
| RV-5×CRW-8 | 9[7] | 2 | (+) | 1 ± 3 | 23 ± 2 | 28 ± 1 |
| Po/TFR-41 | 9[7] | 5 | + | 0 ± 2 | 0 ± 1 | −1 ± 3 |
| RV-5×TFR-41 | 9[7] | 2 | (+) | 2 ± 2 | 24 ± 3 | 22 ± 1 |
| Hu/Wa, RV-4 | 1A[8] | 1 | − | 38 ± 3 | 24 ± 6 | 34 ± 5 |
| Hu/P | 1A[8] | 3 | (−) | 27 ± 1 | 27 ± 2 | 31 ± 4 |
| Hu/VA70 | 1A[8] | 4 | − | 30 ± 2 | 19 ± 6 | 36 ± 2 |
| Hu/K8 | 3[9] | 1 | − | 30 ± 6 | 30 ± 3 | ND |
| Hu/116E | 8[11] | 9 | (−) | 36 ± 6 | ND | ND |
| Po/MDR-13 | 13[13] | 3 and 5 | (−) | 3 ± 2 | 1 ± 3 | 0 ± 3 |
| Ty/Ty-1 | [17] | 7 | − | −2 ± 3 | 2 ± 3 | −1 ± 1 |
Laboratory-adapted rotaviruses are shown with strain name preceded by species of origin. Bo, bovine; Si, simian; Hu, human; Po, porcine; Ty, turkey. In laboratory-generated reassortants (shown in italics), VP7 and VP4 originated from the first- and last-named virus, respectively (27, 32, 33, 39, 40). UK×SA11, UK×RRV, Ty-1×RRV, and RRV×UK were originally designated as R2/1-2, 28-1, TyRh, and 12-1, respectively.
Serotypes designations are as previously described (8, 24, 31). P serotype precedes P genotype, which is shown in square brackets.
Terminal SA usage (+, −) determined previously (8) or inferred [(+), (−)] from identity of P serotype and species of origin with a tested rotavirus strain.
Data are for MAbs at saturating levels of 20 μg/ml (anti-α2 MAb AK7), 40 μg/ml (anti-β2 MAb MHM23), and 10 μg/ml (anti-αVβ3 MAb LM609). Positive levels of MAb blockade (>10%) are in bold. With the exceptions of K8×SA11, RV-5×SA11, and MDR-13×UK, viruses also were tested at four additional serial twofold MAb dilutions, to 1.2 or 2.5 μg/ml, in 3 to 10 experiments. The percent infectivity blockade of integrin-dependent viruses was MAb dose dependent. Integrin-independent viruses showed no blockade at any MAb concentration tested. At 1.2 to 40 μg/ml, MOPC21 MAb did not affect infectivity of any virus. ND, not done.